Microtubule Gene Variants Produced Gene-Specific Neurodevelopmental Patterns in Eleven Patients
Microtubule-related gene variants were associated with a wide neurodevelopmental spectrum in 11 patients, but the clinical patterns were not random. The cohort, drawn from pediatric genetics practice, centered on variants in TUBA1A, TUBB2A, TUBB4A, and TUBGCP6, and each gene tracked with a different bedside phenotype. Global developmental delay appeared in every patient. Seizures were almost as common, and structural brain abnormalities were frequent enough to shape the diagnostic picture in most cases.
One finding stood out immediately: severe neurologic disease clustered around the tubulin genes, while a TUBGCP6 variant presented with a different profile dominated by growth and head-size abnormalities rather than epilepsy.
Cortical Malformation and Epilepsy Clustered Around TUBA1A and TUBB2A
The most striking cerebral malformations were seen in the four patients with TUBA1A variants. Their imaging and clinical course fit a severe neuronal migration disorder, including lissencephaly and pachygyria. Developmental regression was documented in two of those four patients, a sign of early and substantial disruption in brain wiring rather than a static delay alone. When microtubules fail during neuronal migration, the cortex can lose the layered architecture needed for higher-order function, and the phenotype here followed that biology closely.
The four patients with TUBB2A variants were even more epileptically burdened. All four had severe developmental impairment and drug-resistant epilepsy, with syndromic epileptic presentations that included infantile epileptic spasms syndrome and Lennox–Gastaut syndrome. Some also had sound-induced reflex seizures, a dramatic feature that points to a hyperexcitable cortex with abnormal sensory network gating. None of the TUBB2A patients experienced developmental regression, which creates a useful clinical distinction from the TUBA1A group even within the same broad category of tubulin-related disease.
The seizure burden across the entire cohort was high: 9 of 11 patients had seizures, including 8 with epilepsy and 1 with an isolated febrile seizure. Structural brain abnormalities were seen in 7 patients, while 4 had normal MRI findings. In a disorder family like this, a normal MRI cannot exclude a pathogenic variant; the molecular lesion may still disrupt neuronal function, axonal trafficking, or microtubule dynamics in ways that are invisible on routine imaging.
Normal Brain MRI Did Not Exclude a Pathogenic Microtubule Disorder
The four patients with normal neuroimaging deserve special attention because they prevent oversimplification of the phenotype. Developmental delay remained universal, even when MRI did not show malformations. In practical terms, that means a child with profound developmental impairment and epilepsy may still carry a microtubule-related variant despite a nondiagnostic scan.
This matters because the diagnostic reflex in pediatrics often leans heavily on imaging. Here, the molecular findings carried the stronger explanatory weight. The gene itself helped define the syndrome, not just the brain scan.
TUBB4A and TUBGCP6 Broadened the Clinical Range
The two patients with TUBB4A variants showed distinct clinical presentations, indicates the heterogeneity inside microtubule biology. One patient also had systemic lupus erythematosus, a coexisting autoimmune disease that widens the clinical context but does not, from this dataset, establish causality. The abstract does not provide enough detail to assign a mechanistic link between the tubulin variant and the autoimmune condition, and it should not be forced into one.
The TUBGCP6 case diverged most clearly from the epilepsy-heavy pattern seen in the tubulin genes. That patient primarily presented with microcephaly, short stature, and developmental delay without epilepsy. In other words, microtubule-related disease here did not always announce itself through seizures. Growth failure and head size reduction can be the first visible clues, especially when cortical malformation is absent or subtle.
Variant Classes and Structural Modeling Pointed to Protein-Specific Effects
Twelve variants were identified across the 11 patients. Ten were missense variants, one was a noncanonical intronic or splice-region variant, and one was a copy-number duplication. This spread matters because it shows the study was not limited to a single molecular mechanism. Missense changes can distort local folding, alter residue contacts, or destabilize the protein scaffold; splice-region changes can disrupt transcript architecture; copy-number changes can alter dosage.
Computational modeling added a second layer of interpretation. AlphaFold 3 was used to predict protein structures, and FoldX estimated changes in stability and folding free energy. The clearest example was TUBA1A p.Tyr172Asp, which was predicted to increase energy by 5.15 kcal/mol, consistent with a destabilizing effect. For TUBB4A p.Gly10Ser, the structural analysis suggested altered hydrogen bonding. These are not clinical endpoints, but they provide a plausible molecular bridge between genotype and phenotype by showing how a single residue substitution may perturb the microtubule subunit’s geometry or interaction network.
That structural perturbation likely matters most during neurodevelopment, when microtubules are doing essential work in neuronal migration, axonal transport, and mitotic spindle function. A small change in protein stability can become a large developmental problem if it lands in a critical domain or at a residue required for subunit packing.
What the Cohort Adds to Pediatric Genetics Practice
This series strengthens the idea that microtubule-related disorders are not interchangeable. TUBA1A leaned toward severe cortical malformation and possible regression. TUBB2A tracked with severe developmental impairment, epilepsy, and in some cases reflex seizures. TUBB4A was more variable, and TUBGCP6 presented with growth and head-size abnormalities without epilepsy.
For clinicians, the implication is straightforward: severe developmental delay with or without seizures should trigger consideration of this gene family, even when MRI is normal. The pattern of neurologic involvement may help prioritize which gene to suspect first, but the phenotype is broad enough that sequencing remains essential.
The study also reinforces the value of structural bioinformatics in rare disease genetics. AlphaFold 3 and FoldX do not replace clinical observation, but they can help explain why two variants in the same pathway produce different syndromes. The limitations are equally plain: the cohort was small, the structural findings were computational, and the abstract does not provide longitudinal treatment response or broader functional validation. Those gaps leave open how these predictions map onto protein behavior in vivo and whether particular variant classes consistently predict severity across larger patient groups.